Roche: HY 2016 Results (Roche) - Jul 23, 2016 - Anticipated initiation of P3 IMvigor 130 trial (NCT02807636) of Tecentriq + gemcitabine and carboplatin for 1L cisplatin-ineligible metastatic urothelial cancer in Q3 2016; Anticipated initiation of arm D in P1 trial (NCT02715531) of Tecentriq + vanucizumab/Avastin in HCC in Q3 2016; Anticipated data presentation from P1 trial (NCT01633970) in ovarian cancer at ESMO (October 7-11, 2016); Anticipated data presentation from P1 trial (NCT01988896) of Tecentriq + Cotellic in CRC at ESMO (October 7-11, 2016); Anticipated data presentation from P2 BIRCH trial (NCT02031458) in PDL1+ NSCLC at IASLC (December 4-7, 2016)
Anticipated P1 data • Anticipated P2 data • Anticipated trial initiation date • Trial status • Biosimilar • Colorectal Cancer • Hepatocellular Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer
|